NCBR: 'Inviragen’s sale this month likely to boost investor interest in NoCo bioscience firms'

Quoting from the article by Steve Lynn:

"'Fort Collins and Northern Colorado are starting to get some credibility behind the cluster that’s growing there,' said April Giles, chief executive of the Colorado BioScience Association in Denver. 'I think investors are starting to look at that cluster and realize that there’s good momentum and really great opportunity for partnership on the ground.'

Privately held Inviragen, based in Fort Collins with facilities in Madison, Wis., and Singapore, specializes in research and development of vaccines for infectious diseases such as dengue; hand, foot and mouth disease; and chikungunya, a viral disease transmitted by mosquito bites that can cause illness. Established in 2005, the company makes DENVax, a dengue vaccine that is being evaluated in phase 2 clinical trials. It employs about 50 people."

Link to the Northern Colorado Business Report